Search

Displaying results 5681 - 5690 of 9887 in total
  1. Drug

    VaxSyn

    go.drugbank.com/drugs/DB17827
    Investigational

    VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).

  2. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.

  3. Drug

    OAV201

    go.drugbank.com/drugs/DB17842
    Experimental

    OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter

  4. Drug

    AAV1-FS344

    go.drugbank.com/drugs/DB17855
    Investigational

    AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.

  5. Drug

    SAR-439459

    go.drugbank.com/drugs/DB17864
    Investigational

    SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody.[A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.

  6. Drug

    MANF

    go.drugbank.com/drugs/DB17885
    Experimental

    MANF is a human recombinant mesencephalic, astrocyte-derived neurotrophic factor.

  7. Drug

    GIVI-MPC

    go.drugbank.com/drugs/DB17905
    Experimental

    GIVI-MPC is a therapy that uses human-induced pluripotent stem cell-derived myogenic progenitor cells.

  8. Drug

    ALMB-0166

    go.drugbank.com/drugs/DB17937
    Investigational

    ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.[L47067]

  9. Drug

    Bepranemab

    go.drugbank.com/drugs/DB17945
    Investigational

    Bepranemab is a recombinant humanized Igg4P monoclonal antibody directed against human Tau.

  10. Drug

    RPI-MN

    go.drugbank.com/drugs/DB17957
    Experimental

    RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties.